基于基因表达谱分析对葡萄膜黑色素瘤患者进行风险适配管理的前瞻性评估。
Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling.
作者信息
Schefler Amy C, Skalet Alison, Oliver Scott Cn, Mason John, Daniels Anthony B, Alsina Katherina M, Plasseraud Kristen M, Monzon Federico A, Firestone Brian
机构信息
Retina Consultants of Houston, Houston, TX 77030, USA.
Dept. of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR 97239, USA.
出版信息
Melanoma Manag. 2020 Mar 11;7(1):MMT37. doi: 10.2217/mmt-2020-0001.
AIM
The Clinical Application of DecisionDx-UM Gene Expression Assay Results study aimed to evaluate the clinical utility of the prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) patients in a large, prospective multicenter cohort.
PATIENTS & METHODS: Nine centers prospectively enrolled 138 UM patients clinically tested with the 15-GEP. Physician-recommended specialty referrals and metastatic surveillance regimens were collected.
RESULTS
A total of 93% of high-risk class 2 patients were referred to medical oncology for follow-up, compared with 51% of class 1 patients. A majority (62%) of class 2 patients were recommended overall high-intensity metastatic surveillance, while 85% of class 1 patients were recommended low-intensity metastatic surveillance.
CONCLUSION
Treatment plan recommendations for UM patients are aligned with GEP-informed metastatic risk, consistent with prior studies.
目的
“DecisionDx-UM基因表达检测结果的临床应用”研究旨在评估预后15基因表达谱（15-GEP）检测在一个大型前瞻性多中心队列中对葡萄膜黑色素瘤（UM）患者的临床效用。
患者与方法
九个中心前瞻性纳入了138例接受15-GEP临床检测的UM患者。收集了医生推荐的专科转诊和转移监测方案。
结果
共有93%的高危2类患者被转诊至肿瘤内科进行随访，而1类患者的这一比例为51%。大多数（62%）2类患者被推荐进行总体高强度转移监测，而85%的1类患者被推荐进行低强度转移监测。
结论
UM患者的治疗方案建议与基于GEP的转移风险一致，与先前研究相符。
Zotero 插件